Background: Acute pain crisis is the most common reason for individuals with Sickle Cell Disease (SCD) to seek medical attention. The lack of a standardized treatment approach during pain crises leads to inefficient and costly care, resulting in a significant burden on the healthcare system. Objective: To decrease inpatient length of stay and overall cost by redesigning the care of the SCD patient population. Design: A retrospective original investigation involving a clinical redesign with multidisciplinary collaboration. Setting: Bridgeport Hospital (BH), Bridgeport, CT, a member of the Yale New Haven Health System affiliated with Yale University School of Medicine. Participants: All patients admitted to BH with pain crisis. Interventions: Starting June 2015, patients at BH received treatment one of two ways: either in the ED per their pre-prepared treatment plan and were discharged to home, or were admitted to a specifically designated sickle cell service run by hospitalists in cooperation with a multidisciplinary team (where they initially received treatment with self-administered patient-controlledanalgesia) and were then transitioned back to their home oral regimen within a designated time period. Upon discharge, all patients were referred to follow-up at the newly established sickle cell medical home. Main Measures: Length of stay and cost. Key Results: Since the inception of the SCD program, average length of stay decreased by 36% (maximum of 68%), average cost per encounter decreased by 28% (maximum 61%), and average cost per patient decreased by 34% (maximum 73%). This has already garnered a savings of nearly $1,000,000. There was also a rise in the number of patients as the program attracted more SCD patients from the community to BH. Despite this increase, total ED visits decreased as did the number of overall admissions; concurrently, outpatient visits increased. Conclusion: By redesigning the approach of treatment to the SCD population, hospitals can improve value in care.